Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMGEL vs ROXICET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Treatment of acne vulgaris (FDA-approved),Topical treatment of inflammatory acne (FDA-approved),Ophthalmic infections: prophylaxis of neonatal conjunctivitis (off-label),Treatment of bacterial infections of the skin (off-label)
Management of moderate to severe pain where an opioid analgesic is appropriate
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 m L/min).
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces.
Oxycodone is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; acetaminophen is metabolized via conjugation (glucuronidation and sulfation) and by CYP2E1 (minor, but produces toxic NAPQI).
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
70–80%, primarily to albumin.
Oxycodone: 45-50% (primarily albumin). Acetaminophen: 10-25% (minimal).
0.9–1.1 L/kg; indicates extensive extravascular distribution.
Oxycodone: 2.6 L/kg; large Vd indicates extensive tissue distribution.
Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%.
Oral oxycodone: 60-87%; Acetaminophen: 75-85%.
No dosage adjustment required for topical use.
e GFR 30-60 m L/min: reduce dose to 50-75% of usual. e GFR 10-29 m L/min: reduce dose to 25-50% of usual. e GFR <10 m L/min: avoid use or use with extreme caution; reduce dose to 25% and extend dosing interval to every 8-12 hours.
No dosage adjustment required for topical use.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce starting dose by 50% (e.g., oxycodone 2.5-5 mg) and monitor. Child-Pugh Class C: avoid use or use with extreme caution; reduce dose to 25% and extend interval.
Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily.
Weight-based: oxycodone 0.05-0.15 mg/kg per dose, acetaminophen 10-15 mg/kg per dose, orally every 4-6 hours as needed; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day) in children ≥12 years; for children <12 years, max acetaminophen 75 mg/kg/day (max 325 mg per dose in children <6 years).
No specific dose adjustment; use caution due to potential skin atrophy in elderly.
Start with lowest available dose (oxycodone 2.5-5 mg); consider extended dosing interval (every 6-8 hours); monitor renal and hepatic function; avoid in patients with advanced liver disease or GFR <30 m L/min.
No FDA black box warning for topical erythromycin.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity associated with acetaminophen.
May cause irritation, burning, stinging, or dryness at application site,Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic,Superinfection may occur with prolonged use,Potential for bacterial resistance with prolonged use
Respiratory depression; increased intracranial pressure; severe hypotension; hepatotoxicity (acetaminophen); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; risks of use in patients with gastrointestinal obstruction; seizures; severe renal impairment.
Hypersensitivity to erythromycin or any component of the formulation,Not for use in patients with known hepatic impairment (relative contraindication for systemic use, but topical use is generally safe)
Significant respiratory depression; acute or severe bronchial asthma; known hypersensitivity to oxycodone, acetaminophen, or any component; suspected or known gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment.
No known food interactions. Avoid alcohol as it may increase risk of gastrointestinal irritation if oral salicylates are also used.
Avoid alcohol consumption as it increases the risk of hepatotoxicity from acetaminophen and enhances CNS depression from oxycodone. Grapefruit juice may potentiate oxycodone effects by inhibiting CYP3A4 metabolism; avoid concurrent use. High-fat meals may delay absorption of oxycodone but no specific food restrictions otherwise.
EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester.
Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal dependence and withdrawal; growth restriction possible. Third trimester: High risk of neonatal opioid withdrawal syndrome (NOWS), respiratory depression, and preterm birth; avoid prolonged use.
Tetracyclines are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants exists, but absorption of tetracyclines from milk is limited due to chelation with calcium. Caution is advised; alternative therapies preferred.
Oxycodone is excreted into breast milk; M/P ratio ~3.4 (for oxycodone). Relative infant dose 1.7-6.8% of maternal weight-adjusted dose; may cause infant sedation, respiratory depression, and withdrawal. Use with caution, monitor infant for somnolence and feeding difficulties; avoid if mother is on high doses or has CYP2D6 ultra-rapid metabolizer status.
No dose adjustment required for EMGEL in pregnancy; however, tetracyclines are contraindicated after first trimester. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, decreased plasma protein binding) but no specific dose adjustment recommended due to contraindication. Use only when no alternative and clearly needed.
Increased hepatic clearance and volume of distribution in pregnancy may require dose adjustments. No specific guidelines; consider using lowest effective dose and short-term therapy. Taper if discontinuing to prevent withdrawal. Avoid in labor due to neonatal respiratory depression; reserve for severe pain.
Apply sparingly to affected area; avoid contact with eyes, mucous membranes, and open wounds. Monitor for systemic absorption if used on large body surface areas. Use caution in patients with renal impairment due to potential for salicylate toxicity. Do not use with other topical preparations containing methyl salicylate.
ROXICET contains oxycodone (an opioid agonist) and acetaminophen. Always assess pain severity and opioid tolerance before prescribing. Monitor for respiratory depression, especially in opioid-naive patients. The maximum daily acetaminophen dose is 4 g (consider hepatic impairment and alcohol use). Avoid concurrent use of other acetaminophen-containing products. Prescribe naloxone for patients at risk of overdose. Use with caution in elderly, renal impairment, and respiratory conditions.
Wash hands before and after application.,Apply only to intact skin, not on wounds or damaged skin.,Do not use with heating pads or bandages unless directed by doctor.,Avoid sun exposure to treated area as it may cause photosensitivity.,Discontinue if rash or irritation occurs and consult doctor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Do not consume alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication.,Risk of dependence; do not share this medication with others. Store securely out of reach of children and pets.,Dispose of unused medication via a drug take-back program or mix with unpalatable substances and seal in a plastic bag before discarding.,Contact your doctor if you experience signs of allergic reaction (rash, itching, swelling), severe constipation, nausea/vomiting, or difficulty breathing.,Avoid taking other acetaminophen-containing products; do not exceed 4,000 mg of acetaminophen per day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMGEL vs ROXICET, answered by our medical review team.
EMGEL is a Topical Antibiotic that works by Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.. ROXICET is a Opioid Analgesic Combination that works by Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMGEL and ROXICET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMGEL is: Topical application of a thin layer to affected area twice daily; oral administration not applicable.. The standard adult dose of ROXICET is: 1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMGEL and ROXICET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMGEL is classified as Category C. EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and te. ROXICET is classified as Category C. Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.